

CorNotes

CVI SEMINAR SERIES

The next CVI Seminar will be held on **Thursday, March 15, 2007 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6294**. Our speaker is:

Christopher Turner, Ph.D.
Professor of Cell and Developmental Biology
SUNY-Upstate Medical University
Syracuse, NY

The title Dr. Turner's talk is:

"Paxillin Family Members and Epithelial-Mesenchymal Transition"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

March 8.....Dr. Mestril
March 22.....Dr. Hoppensteadt

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm 5215. For further information, contact Dr. Ken Byron at x72819.

CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

March 15.....Dr. Joseph Akar

The title of Dr. Akar's talk is:

"Basic Cardiac Electrophysiology"

For further information, contact Dr. Samarel at x72821

MEND-CABG II TRIAL

Dr. Mamdouh Bakhos, Chairman of the Department of Thoracic and Cardiovascular Surgery, is the Principal Investigator conducting the MEND-CABG II clinical trial in cooperation with Medicare International. This is a randomized, double-blind, placebo-controlled, multicenter study.

The primary objective is to determine the effect of MC-1 (pyridoxal 5'-phosphate monohydrate) on the combined incidence of cardiovascular death and nonfatal myocardial infarction up to and including 30 days following coronary artery bypass graft (CABG) surgery compared to placebo. The secondary objective is to confirm the safety of MC-1 administered in the peri-CABG setting. The goals of the economic sub-study are to compare selected medical resource use patterns and medical costs for the MC-1 arm vs. the placebo arm by intention-to-treat in patients randomized into MEND-CABG II.

Patients must be greater than 18 years of age, scheduled to have coronary artery bypass surgery, and be considered to be at high risk for surgery. Conditions that put someone at higher risk for surgery include age greater than 65 years, having diabetes, smoking, history of a stroke or carotid artery disease, impaired kidney function, having a heart attack in the 6 months before bypass surgery, or history of congestive heart failure.

Patients will receive 250 mg of MC-1 or placebo once daily for 30 days after coronary artery bypass surgery. They will also receive one dose 3-10 hours before surgery begins.

For more information or to alert the Thoracic and Cardiovascular Surgery team of potential participants, please contact the project's coordinator, Sally Botkin, at 708-327-2494.

